270 related articles for article (PubMed ID: 17275980)
21. Botulinum toxin in the treatment of OAB, BPH, and IC.
Smith CP
Toxicon; 2009 Oct; 54(5):639-46. PubMed ID: 19268490
[TBL] [Abstract][Full Text] [Related]
22. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion.
Kuo HC
Neurourol Urodyn; 2008; 27(8):793-6. PubMed ID: 18508331
[TBL] [Abstract][Full Text] [Related]
23. Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature.
Moore DC; Cohn JA; Dmochowski RR
Toxins (Basel); 2016 Mar; 8(4):88. PubMed ID: 27023601
[TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin--new mechanisms, new therapeutic directions?
Chapple C; Patel A
Eur Urol; 2006 Apr; 49(4):606-8. PubMed ID: 16457945
[No Abstract] [Full Text] [Related]
25. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Fowler CJ
Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958
[No Abstract] [Full Text] [Related]
26. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Schurch B
Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956
[No Abstract] [Full Text] [Related]
27. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin in urology: evaluation using an evidence-based medicine approach.
Smith CP; Somogyi GT; Boone TB
Nat Clin Pract Urol; 2004 Nov; 1(1):31-7. PubMed ID: 16474464
[TBL] [Abstract][Full Text] [Related]
29. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
Sahai A; Khan MS; Dasgupta P
J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
[TBL] [Abstract][Full Text] [Related]
31. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
[TBL] [Abstract][Full Text] [Related]
32. Editorial comment on: neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
Wyndaele JJ
Eur Urol; 2008 May; 53(5):1019-20. PubMed ID: 17950988
[No Abstract] [Full Text] [Related]
33. [Detrusor-sphincter dyssynergia and botulinum toxin].
Parratte B; Bonniaud V; Tatu L; Metton G; Michel F; Cosson A; Monnier G
Ann Readapt Med Phys; 2003 Jul; 46(6):319-25. PubMed ID: 12928137
[TBL] [Abstract][Full Text] [Related]
34. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
Apostolidis A; Jacques TS; Freeman A; Kalsi V; Popat R; Gonzales G; Datta SN; Ghazi-Noori S; Elneil S; Dasgupta P; Fowler CJ
Eur Urol; 2008 Jun; 53(6):1245-53. PubMed ID: 18343564
[TBL] [Abstract][Full Text] [Related]
35. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results.
Karsenty G; Baazeem A; Elzayat E; Corcos J
Can J Urol; 2006 Apr; 13(2):3027-33. PubMed ID: 16672114
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
[TBL] [Abstract][Full Text] [Related]
37. Intravesical injection of botulinum toxin for the treatment of overactive bladder.
Ho MH; Lin LL; Haessler AL; Bhatia NN
Curr Opin Obstet Gynecol; 2005 Oct; 17(5):512-8. PubMed ID: 16141766
[TBL] [Abstract][Full Text] [Related]
38. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
Lemack GE
Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
[No Abstract] [Full Text] [Related]
39. Botulinum toxin injection therapy in the management of lower urinary tract dysfunction.
Patel AK; Chapple CR
Int J Clin Pract Suppl; 2006 Dec; (151):1-7. PubMed ID: 17169004
[TBL] [Abstract][Full Text] [Related]
40. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
Lucioni A; Bales GT; Lotan TL; McGehee DS; Cook SP; Rapp DE
BJU Int; 2008 Feb; 101(3):366-70. PubMed ID: 18184328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
